Q-omics provides the consensus-scored SPTY2D1OS profile across patient tissues and cancer cell-line models. SPTY2D1OS expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SPTY2D1OS is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, SPTY2D1OS RNA expression shows 17,132 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where SPTY2D1OS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPTY2D1OS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPTY2D1OS survival associations across molecular data types. SPTY2D1OS RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPTY2D1OS RNA expression–survival associations across cancer types. High SPTY2D1OS expression shows unfavorable associations in KIRC, LIHC, COAD, LGG, UVM and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for SPTY2D1OS RNA expression.
This table summarizes SPTY2D1OS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SPTY2D1OS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPTY2D1OS shows lower tumor expression in KIRC and higher tumor expression in COAD, LIHC, CHOL, LUSC and LUAD. The COAD box plot shows higher SPTY2D1OS RNA expression in tumor versus normal tissue (log2 FC = +0.574, t-test p < 0.001).
This table shows molecular features associated with SPTY2D1OS in patient tissues and cancer cell lines. In patient samples, SPTY2D1OS shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SPTY2D1OS RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma.
